NEW YORK, Sept. 27, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (“MindMed”) (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the pricing of its underwritten public offering of 7,058,823 common shares, together with accompanying warrants to purchase 7,058,823 common shares.


Previous articleMindset Pharma Provides Strategic Intellectual Property License to Cybin
Next articleReunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer